RNA-based SYNGAP1 program (Stoke Therapeutics/Acadia Pharmaceuticals)

N/A

Report date: 2025/03/20 10:07:28
NME

Base Information

Drug NameRNA-based SYNGAP1 program (Stoke Therapeutics/Acadia Pharmaceuticals)
Drug Alias NameSYNGAP1 modulator (Stoke Therapeutics/Acadia Pharmaceuticals)antisense oligonucleotide (Stoke Therapeutics/Acadia Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionRas/Rap GTPase-activating protein SynGAP modulators
TargetsRas/Rap GTPase-activating protein SynGAP
Therapy Area/IndicationsCentral nervous system development disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStoke Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStoke Therapeutics IncAcadia Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCentral nervous system development disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A